BETA.NS,0P0001BSG7,9300 logo

BETA.NS,0P0001BSG7,9300 (BETA)

Market Closed
10 Aug, 10:00
XNSE XNSE
2,504. 00
+130.3
+5.4893%
14.37B Market Cap
- P/E Ratio
- Div Yield
65,018 Volume
- Eps
2,373.7
Previous Close
Add Transaction
Day Range
2,366 2,579.8
Year Range
990.1 2,674
Want to track BETA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

BETA closed today higher at ₹2,504, an increase of 5.4893% from yesterday's close, completing a monthly increase of 14.0463% or ₹308.4. Over the past 12 months, BETA stock gained 60.0716%.
BETA is not paying dividends to its shareholders.
BETA.NS,0P0001BSG7,9300 has completed 1 stock splits, with the recent split occurring on Mar 26, 2025.
The company's stock is traded on one exchange.

BETA Chart

BETA.NS,0P0001BSG7,9300 (BETA) FAQ

What is the stock price today?

The current price is ₹2,504.00.

On which exchange is it traded?

BETA.NS,0P0001BSG7,9300 is listed on XNSE.

What is its stock symbol?

The ticker symbol is BETA.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 14.37B.

Has BETA.NS,0P0001BSG7,9300 ever had a stock split?

BETA.NS,0P0001BSG7,9300 had 1 splits and the recent split was on Mar 26, 2025.

BETA.NS,0P0001BSG7,9300 Profile

- Industry
- Sector
- CEO
XNSE Exchange
- ISIN
India Country
399 Employees
- Last Dividend
26 Mar 2025 Last Split
- IPO Date

Overview

Beta Drugs Limited is a prominent Indian company founded in 1985, located in Panchkula, India. The organization specializes in the development, manufacturing, and selling of anti-cancer bulk drugs and finished dosages. With a commitment to healthcare advancements, Beta Drugs Limited not only focuses on oncology but also delves into cosmeceutical products. The company is equipped to manufacture active pharmaceutical ingredients (API) and pharmaceutical formulation intermediates (PFI), catering to both domestic and international markets through its export services.

Products and Services

  • Anti-Cancer Bulk Drugs:

    Beta Drugs Limited develops a range of bulk drugs specifically designed for cancer treatment, ensuring high-quality solutions in the fight against various types of cancer. These products are essential for formulating effective treatment regimens and are crafted using advanced techniques.

  • Finished Dosages:

    The company produces finished dosage forms that make it easier for patients to receive necessary treatments. These products encompass a range of formulations tailored to enhance therapeutic efficacy and improve patient compliance.

  • Cosmeceutical Products:

    In addition to oncology, Beta Drugs Limited offers a line of cosmeceuticals, which are cosmetic products with therapeutic benefits. This segment is dedicated to skin health, providing formulations that promote skin repair and rejuvenation.

  • Active Pharmaceutical Ingredients (API):

    The manufacturing of APIs is a core competency of Beta Drugs Limited, producing high-purity ingredients that serve as the foundational components in various pharmaceutical formulations. These APIs are crucial for the development of effective medications.

  • Pharmaceutical Formulation Intermediates (PFI):

    Beta Drugs Limited also focuses on the production of pharmaceutical formulation intermediates, which play a vital role in the drug manufacturing process, helping to streamline and enhance the formulation of end products.

  • Export Services:

    The company exports its pharmaceutical products, expanding its reach to global markets and contributing to international healthcare solutions. This enables Beta Drugs Limited to offer its expertise beyond India, fostering improved health outcomes worldwide.

Contact Information

Address: SCO-184
Phone: 91 17 2258 5481